George A J, McBride H M, Glennie M J, Smith L J, Stevenson F K
Host Immunity to Tumour Group, Tenovus Research Laboratory, Southampton General Hospital, United Kingdom.
Hybridoma. 1991 Apr;10(2):219-27. doi: 10.1089/hyb.1991.10.219.
Anti-idiotypic antibodies can be used as probes to distinguish neoplastic cells from their normal counterparts. In addition they have been used in the passive therapy of B cell tumors. In this report we describe a panel of 7 rat monoclonal antibodies raised against idiotypic determinants carried by the IgM molecule of the BCL1 lymphoma. The majority (6/7) of these antibodies recognize private idiotypic determinants that are carried on the isolated mu heavy chain of the molecule, and do not require the lambda chain for reactivity. This is unusual for antibodies raised against the idiotype of the whole immunoglobulin molecule, which normally require both chains for reactivity. The antibodies do not, however, bind peptides corresponding to the complementarity determining regions of the mu heavy chain of BCL1. The antibodies perform well in complement mediated cytotoxicity, and, in at least one case, are effective in the passive immunotherapy of BCL1 lymphoma.
抗独特型抗体可作为探针，用于区分肿瘤细胞与其正常对应细胞。此外，它们还被用于B细胞肿瘤的被动治疗。在本报告中，我们描述了一组针对BCL1淋巴瘤IgM分子携带的独特型决定簇产生的7种大鼠单克隆抗体。这些抗体中的大多数（6/7）识别该分子分离的μ重链上携带的私有独特型决定簇，并且反应性不需要λ链。对于针对整个免疫球蛋白分子独特型产生的抗体而言，这是不寻常的，这类抗体通常需要两条链才能产生反应。然而，这些抗体并不结合与BCL1的μ重链互补决定区对应的肽段。这些抗体在补体介导的细胞毒性中表现良好，并且至少在一个案例中，对BCL1淋巴瘤的被动免疫治疗有效。
